Results 101 to 110 of about 2,377 (150)

Effectiveness of Siponimod with Up to 2 Years of Treatment in a Real-World Setting in People with SPMS: Analysis from the Novartis Global Managed Access Program. [PDF]

Degener Neurol Neuromuscul Dis
Carotenuto A, Naoumis D, Brescia Morra V, Kouremenos E, Hetherington S, Arnould S, Heras VL.   +6 more
europepmc   +1 more source

Therapeutic reactivation of hippocampal progenitors reverse cognition decline in mice with progressive brain demyelination. [PDF]

Stem Cell Reports
Nemati S, Hosseini SM, Bravo-Jimenez MA, Karimi-Abdolrezaee S.   +3 more
europepmc   +1 more source

Effects of Sphingosine 1-phosphate Modulators on Central Remyelination: A Systematic Review of Animal Models. [PDF]

Cell Mol Neurobiol
Vu H, George N, Xiao J.
europepmc   +1 more source

Loss of oligodendrocyte transcription factor 2 protein expression in metabolically stressed oligodendrocytes. [PDF]

Acta Neuropathol
Kaddatz H, Wenzel L, Pril E, Meien S, Harz V, Burkert L, Behrangi N, Zimmermann A, Frintrop L, Amor S, Kipp M, Heinig L.   +11 more
europepmc   +1 more source

Predictors of high- versus low-intensity first-line multiple sclerosis treatments. [PDF]

Mult Scler J Exp Transl Clin
Chevalier AVG, Murray K, Lin A, Kerber K, Burke JF, Gyang TV.   +5 more
europepmc   +1 more source

Structural insights into subtype-specific agonist recognition by sphingosine-1-phosphate receptors. [PDF]

PLoS Biol
Yu L, Jiao H, Pang B, Ti R, Gan B, Qin Z, Wang J, Zhu L, Hu H, Ren R.   +9 more
europepmc   +1 more source

Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study. [PDF]

J Neurol
Maniscalco GT, Sparaco M, Di Gregorio M, Cafasso G, Signoriello E, Romano F, Iodice R, Fantozzi R, Bellantonio P, Zanghi A, Sinisi L, D'Ambrosio A, Busillo V, Scarano V, Capuano R, Lavorgna L, Williams M, De Martino A, Di Battista ME, Di Giulio Cesare D, Lus G, Cassano E, Di Filippo PS, Sibilia G, Abbadessa G, Andreone V, Bonavita S.   +26 more
europepmc   +1 more source

The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry. [PDF]

J Neurol
Guger M, Enzinger C, Heschl B, Di Pauli F, Gradl C, Kalcher S, Kvas E, Berger T, Austrian MS Treatment Registry (AMSTR).   +8 more
europepmc   +1 more source

Efficacy and safety of mesenchymal stem cell transplantation for progressive multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials with clinical implications for patient stratification and treatment optimization. [PDF]

Front Immunol
Guo H, Zeng L, Sun L.
europepmc   +1 more source

Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study. [PDF]

Mult Scler
Fox RJ, Cohan S, Mao-Draayer Y, Weinstock-Guttman B, Cruz LA, Arnould S, Cox GM, Bar-Or A.   +7 more
europepmc   +1 more source